Treatment of multiple sclerosis with interferon β1b

被引:0
|
作者
Dhib-Jalbut, S
McFarland, HF
机构
[1] Univ Maryland Hosp, Dept Neurol, Baltimore, MD 21201 USA
[2] NINCDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
来源
BAILLIERES CLINICAL NEUROLOGY | 1997年 / 6卷 / 03期
关键词
interferon beta(1b); Betaseron; multiple sclerosis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interferon beta(1b) is now an established therapeutic option for relapsing remitting multiple sclerosis. More recently, it has also been shown to slow down disease progression in secondary progressive multiple sclerosis. Interferon beta(1b)'s clinical effect is reflected in MRI studies demonstrating a dramatic effect in reducing disease activity. The drug is generally well tolerated, but its efficacy can be compromised in some patients by the emergence of neutralizing antibodies. This chapter will focus on interferon beta(1b) (Betaseron) treatment for multiple sclerosis, its clinical and MRI effects, and its putative mechanism of action.
引用
收藏
页码:467 / 480
页数:14
相关论文
共 50 条
  • [41] Nephrotic syndrome associated with interferon-β-1b therapy for multiple sclerosis
    Kumasaka R.
    Nakamura N.
    Shirato K.
    Fujita T.
    Murakami R.
    Shimada M.
    Nakamura M.
    Osawa H.
    Yamabe H.
    Okumura K.
    Clinical and Experimental Nephrology, 2006, 10 (3) : 222 - 225
  • [42] Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis
    Goodin, D. S.
    Hurwitz, B.
    Noronha, A.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2008, 36 (01) : 208 - 210
  • [43] The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b
    Rice, GPA
    Paszner, B
    Oger, J
    Lesaux, J
    Paty, D
    Ebers, G
    NEUROLOGY, 1999, 52 (06) : 1277 - 1279
  • [44] Stabilisation under Interferon β-1b in Late-Onset Multiple Sclerosis
    Lindquist, S.
    Stangel, M.
    AKTUELLE NEUROLOGIE, 2012, 39 : S31 - S33
  • [45] Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis
    Monzani, F
    Caraccio, N
    Meucci, G
    Lombardo, F
    Moscato, G
    Casolaro, A
    Ferdeghini, M
    Murri, L
    Ferrannini, E
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 141 (04) : 325 - 331
  • [46] Treatment of multiple sclerosis with interferon beta-1b
    AbdulAhad, A
    Shah, S
    Galazka, A
    NEUROLOGY, 1997, 49 (02) : 641 - 641
  • [47] Multiple sclerosis treatment: interferon-beta-1b
    Kruja, J.
    Rakacolli, M.
    Prifti, V.
    Mijo, S.
    Zekja, I.
    Kiku, E.
    MULTIPLE SCLEROSIS, 2006, 12 : S188 - S188
  • [48] Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
    Kappos, L
    Polman, C
    Pozzilli, C
    Thompson, A
    Dahlke, F
    Knight, R
    Hern, J
    Coleman, R
    Gerrie, L
    Cooper, G
    Moore, J
    Boringa, J
    van Oosten, B
    Ronner, H
    Schrijver, H
    Truyen, L
    Montalbán, J
    Río, J
    Tintoré, M
    Jacas, C
    Marzo, E
    Lechner-Scott, J
    Huber, S
    Lienert, C
    Brunnschweiler, H
    Hawkins, S
    Droogan, A
    McDonnell, G
    Duddy, M
    McKinstry, S
    Altenkirch, H
    Baum, K
    Einhäupl, K
    Marx, P
    Poewe, W
    Walter, G
    Akman, H
    Brockmeier, B
    Scherer, P
    Zschenderlein, R
    Schmierer, K
    Gelderblom, H
    Hartmann, A
    Stapf, C
    Lüschow, A
    Mackert, B
    Schumacher, H
    Masuhr, F
    Hempel, T
    Zimmermann, R
    LANCET, 1998, 352 (9139): : 1491 - 1497
  • [49] Thyroid autoimmunity disorders during interferon β-1b treatment in patients with multiple sclerosis:: review and case report
    Lange-Asschenfeldt, C
    Boor, S
    Kahaly, GJ
    Thömke, F
    NERVENARZT, 2004, 75 (06): : 589 - +
  • [50] Simultaneous Treatment of Both Hepatitis C and Multiple Sclerosis Using Interferon-beta 1b (Betaseron®)
    Srivatsa, Arun
    Maliakkal, Benedict
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S292 - S292